TY - JOUR
T1 - Impact of the Coronavirus Disease 2019 Pandemic on Physical and Mental Health of Patients with COPD
T2 - Results from a Longitudinal Cohort Study Conducted in the United States (2020-2021)
AU - American Lung Association Airways Clinical Research Centers
AU - Zhang, William Z.
AU - LaBedz, Stephanie L.
AU - Holbrook, Janet T.
AU - Gangemi, Andrew
AU - Baalachandran, Ramasubramanian
AU - Eakin, Michelle N.
AU - Wise, Robert A.
AU - Sumino, Kaharu
N1 - Funding Information:
Abbreviations: chronic obstructive pulmonary diseases, COPD; coronavirus disease 2019, COVID-19; Losartan Effects on Emphysema Progression, LEEP; forced expiratory volume in 1 second, FEV1; high-resolution computed tomography, HRCT; Airways Clinical Research Centers, ACRC; bronchodilator, BD; forced vital capacity, FVC; COPD Assessment Test, CAT; Generalized Anxiety Disorder-7 questionnaire, GAD-7; Patient Health Questionnaire, PHQ-8; Patient-Reported Outcome Measurement Information System, PROMIS; National Institutes of Health, NIH; interquartile range, IQR Funding Support: This research was funded by grants from the American Lung Association and the National Institutes of Health-National Heart, Lung and Blood Institute (U01HL128951 and U01HL128954). Clinical Trial Registration: NCT00720226. Date of Acceptance: August 17, 2022 | Published Online Date: August 23, 2022 Citation: Zhang WZ, LaBedz SL, Holbrook JT, et al; the American Lung Association Airways Clinical Research Centers. Impact of the coronavirus disease 2019 pandemic on physical and mental health of patients with COPD: results from a longitudinal cohort study conducted in the United States (2020-2021). Chronic Obstr Pulm Dis. 2022;9(4):510-519. doi: https://doi.org/10.15326/jcopdf.2022.0287
Publisher Copyright:
© 2022 COPD Foundation. All rights reserved.
PY - 2022
Y1 - 2022
N2 - Background: Patients with chronic obstructive pulmonary disease (COPD) are at higher risk for severe coronavirus disease 2019 (COVID-19). From the pandemic’s onset there has been concern regarding effects on health and wellbeing of high-risk patients. Methods: This was an ancillary study to the Losartan Effects on Emphysema Progression (LEEP) Trial and was designed to collect descriptive information longitudinally about the health and wellbeing of COPD patients who were enrolled in a clinical trial. Participants were interviewed by telephone about their health status every 2 weeks and their mental health, knowledge, and behaviors every 8 weeks from June 2020 to April 2021. There were no prespecified hypotheses. Results: We enrolled 157 of the 220 participants from the parent LEEP trial. Their median age was 69 years, 55% were male, and 82% were White; median forced expiratory volume in 1 second (FEV1)% predicted was 48%. Nine confirmed COVID-19 infections were reported, 2 resulting in hospitalization. Rates of elevated anxiety or depressive symptoms were 8% and 19% respectively in June 2020 and remained relatively stable during follow-up. By April 2021, 85% of participants said they were “very likely” to receive a vaccine; 91% were vaccinated (≥1 dose) by the end of December 2021. Conclusions: Our select cohort of moderate to severe COPD patients who were well integrated into a health care network coped well with the COVID-19 pandemic. Few participants were diagnosed with COVID-19, levels of depression and anxiety were stable, most adopted accepted risk reduction behaviors, and did not become socially isolated; most were vaccinated by the end of 2021.
AB - Background: Patients with chronic obstructive pulmonary disease (COPD) are at higher risk for severe coronavirus disease 2019 (COVID-19). From the pandemic’s onset there has been concern regarding effects on health and wellbeing of high-risk patients. Methods: This was an ancillary study to the Losartan Effects on Emphysema Progression (LEEP) Trial and was designed to collect descriptive information longitudinally about the health and wellbeing of COPD patients who were enrolled in a clinical trial. Participants were interviewed by telephone about their health status every 2 weeks and their mental health, knowledge, and behaviors every 8 weeks from June 2020 to April 2021. There were no prespecified hypotheses. Results: We enrolled 157 of the 220 participants from the parent LEEP trial. Their median age was 69 years, 55% were male, and 82% were White; median forced expiratory volume in 1 second (FEV1)% predicted was 48%. Nine confirmed COVID-19 infections were reported, 2 resulting in hospitalization. Rates of elevated anxiety or depressive symptoms were 8% and 19% respectively in June 2020 and remained relatively stable during follow-up. By April 2021, 85% of participants said they were “very likely” to receive a vaccine; 91% were vaccinated (≥1 dose) by the end of December 2021. Conclusions: Our select cohort of moderate to severe COPD patients who were well integrated into a health care network coped well with the COVID-19 pandemic. Few participants were diagnosed with COVID-19, levels of depression and anxiety were stable, most adopted accepted risk reduction behaviors, and did not become socially isolated; most were vaccinated by the end of 2021.
KW - COPD
KW - COVID-19
KW - anxiety
KW - depression
KW - vaccination
KW - vaccine hesitancy
UR - http://www.scopus.com/inward/record.url?scp=85143649812&partnerID=8YFLogxK
U2 - 10.15326/jcopdf.2022.0287
DO - 10.15326/jcopdf.2022.0287
M3 - Article
C2 - 35998338
AN - SCOPUS:85143649812
SN - 2372-952X
VL - 9
SP - 510
EP - 519
JO - Chronic Obstructive Pulmonary Diseases
JF - Chronic Obstructive Pulmonary Diseases
IS - 4
ER -